AI Article Synopsis
- Favipiravir is an oral antiviral medication approved in India for treating mild-to-moderate COVID-19, and this study aimed to evaluate its effectiveness and safety in real-world settings.
- The study involved examining medical records of 360 patients across four centers, finding a high clinical cure rate of over 90% with average recovery times of about four to five days.
- The results indicated that while 8% of patients experienced some adverse effects like liver enzyme elevation and fatigue, these were generally mild and temporary, suggesting favipiravir is a well-tolerated treatment option.
Article Abstract
Background: Favipiravir, an RNA-dependent RNA polymerase inhibitor (RdRp), is a broad-spectrum oral antiviral agent approved in India under emergency use authorization, for the treatment of mild-to-moderate coronavirus disease (COVID-19). The present study was planned to evaluate the effectiveness and safety of favipiravir in real-world clinical practice.
Materials And Methods: This was a multicentric, retrospective, single-arm study conducted across four centres in India, after obtaining permission from the independent ethics committee. Medical records were analysed to evaluate effectiveness and safety of patients who were prescribed favipiravir.
Results: The medical records of a total of 360 patients met the inclusion criteria, with 358 of them available for the final analysis. Males made up 58.46% of the study population. The average age of enrolled patients was 51.80 ± 16.45 years. The most common symptoms were fever, cough, and myalgia-fatigue. The median time to clinical cure and fever relief was five and four days, respectively. The average length of stay in the hospital was six days. In total, 8% of the patients experienced adverse events. Hepatic enzyme elevation, diarrhoea, decreased appetite, headache, fatigue, and giddiness were the common symptoms.
Conclusion: In our real-world study, favipiravir was found to have a clinical cure rate of more than 90% in mild-to-moderate COVID-19 patients. This supports the use of favipiravir in the treatment of COVID-19. Favipiravir was well tolerated, with only minimal side effects, which were transient in nature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154000 | PMC |
| http://dx.doi.org/10.2147/POR.S364066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EVALUATION OF THE EFFECTS OF FAVIPIRAVIR (T-705) ON THE LUNG TISSUE OF HEALTY RATS: AN EXPERIMENTAL STUDY.
Food Chem Toxicol
January 2025
Department of Histology and Embryology, Erciyes University, Faculty of Medicine, 38039 Kayseri, Turkey. Electronic address:
Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor widely used during the COVID-19 pandemic, effectively reduces viral load but has been linked to inflammatory changes in tissues such as the liver and kidneys. High-dose and prolonged use of favipiravir for COVID-19 raises concerns about its potential toxic effects on the lungs, particularly in patients with pre-existing pulmonary conditions. This study investigated favipiravir's effects on lung tissue in healthy rats.
View Article and Find Full Text PDFNew reverse sum Revan indices for physicochemical and pharmacokinetic properties of anti-filovirus drugs.
Front Chem
December 2024
Department of Mathematics, School of Advanced Sciences, Vellore Institute of Technology, Chennai, Tamil Nadu, India.
Ebola and Marburg viruses, biosafety level 4 pathogens, cause severe hemorrhaging and organ failure with high mortality. Although some FDA-approved vaccines or therapeutics like Ervebo for Zaire Ebola virus exist, still there is a lack of effective therapeutics that cover all filoviruses, including both Ebola and Marburg viruses. Therefore, some anti-filovirus drugs such as Pinocembrin, Favipiravir, Remdesivir and others are used to manage infections.
View Article and Find Full Text PDFCo-immobilization of laccase and zinc oxide nanoparticles onto bacterial cellulose to achieve synergistic effect of photo and enzymatic catalysis for biodegradation of favipiravir.
Int J Biol Macromol
December 2024
Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, P.O. Box 48175-861, Sari 4847193698, Iran; Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address:
The environmental persistence of pharmaceuticals represents a significant threat to aquatic ecosystems and human health, while limitations in conventional wastewater treatment methods underscore the urgent need for innovative and eco-friendly degradation strategies. Photobiocatalytic approaches provide a promising solution for the effective degradation of pharmaceutical contaminants by harnessing the synergistic effects of both photocatalysts and biocatalysts. In this study, we developed a photobiocatalytic composite by co-immobilizing laccase enzyme and zinc oxide nanoparticles on bacterial cellulose synthesized from orange peel waste.
View Article and Find Full Text PDFInvestigation of metabolite profiles of kidney tissues in rats treated with favipiravir drug: An NMR-based metabolomics study.
J Pharm Biomed Anal
December 2024
Department of Biomedical Engineering, Inonu University, Malatya, Turkey. Electronic address:
In response to the urgent need for effective treatments during the rapid spread and high mortality rate of COVID-19, existing drugs were repurposed for potential antiviral effects, including favipiravir, originally designed as an RNA-dependent RNA polymerase inhibitor for influenza. Despite limited antiviral effectiveness against COVID-19, favipiravir has been reported to cause several adverse drug events (ADEs) in the body. Recent studies have shown that favipiravir can damage various tissues in rats.
View Article and Find Full Text PDFCan antiviral drugs address the treatment challenges of severe fever with thrombocytopenia syndrome? - a systematic meta-analysis.
J Infect Dev Ctries
November 2024
Department of Administrative, Zhoushan Hospital, Zhoushan, China.
Background: Severe Fever with Thrombocytopenia Syndrome (SFTS) is an emerging infectious disease with high mortality and severity rates. However, there is no clear treatment plan, specific effective antiviral drugs, or effective vaccine for SFTS. Recent studies have shown that the therapeutic effect of Ribavirin and other commonly used antiviral drugs such as Favipiravir (T-705), on SFTS is still controversial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!